Inferra AIResearch Tools

Inferra AI / Company / SYK

Stryker Corporation

SYK · Health Care

Last earnings Oct 29, 2026

Important announcements

Number: 26-19 Date: October 6, 2026Oct 6, 2026Kevin Lobo Strengthened Stryker as a diversified global leader in medical technologies 14 years of transformative leadership Legacy ofOct 6, 2026Spencer Stiles President and Chief Operating Officer Incoming Chief Executive Officer | Effective January 1, 2027 I am honored toOct 6, 2026

Key results

Earnings Analysis Reported net incomequarter

$859 million

Earnings Analysis Reported net earnings of $859 million increased 3.0% in the quarter.

SEC original ↗Stryker Corporation — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Reported net incomequarter

$2.22

Reported net earnings per diluted share of $2.22 increased 2.8% in the quarter.

SEC original ↗Stryker Corporation — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Operating incomequarter

63.6%

Reported gross profit margin and reported operating income margin were 63.6% and 18.7% in the quarter.

SEC original ↗Stryker Corporation — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Adjusted operating incomequarter

25.6%

Excluding the aforementioned items, adjusted gross profit margin (1) was 65.0% in the quarter, and adjusted operating income margin (1) was 25.6% in the quarter.

SEC original ↗Stryker Corporation — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Adjusted net incomequarter

$1.2 billion

Adjusted net earnings (1) of $1.2 billion increased 11.4% in the quarter.

SEC original ↗Stryker Corporation — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Adjusted net earnings per diluted share (1) of $3.19 increased 11.1% in the quarter.

SEC original ↗Stryker Corporation — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Net EPSquarter

3.2 %

Net earnings per share of common stock Basic $ 2.25 $ 2.18 3.2 % $ 6.27 $ 6.42 (2.3) %

SEC original ↗Stryker Corporation — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Net incomequarter

$ 33

, deal costs and legal entity rationalization) 9 10 Adjustments to Operating Income $ 39 $ 48 Other income taxes related to acquisition and integration-related costs 6 11 Adjustments to Income Taxes $ 6 $ 11 Adjustments to Net Earnings $ 33 $ 37 (b) Structural optimization and other special charges represent the costs associated with Three Months 2025 2024 Employee retention and workforce reductions $ 5 $ 12 Closure transfer of manufacturing and other facilities (e.

SEC original ↗Stryker Corporation — Earnings release (8-K exhibit)EX-99Oct 30, 2025

AI analysis

Q3 2025 · reported Oct 30, 2025

Based on: Earnings release + parent 8-K — transcript not held

Earnings Analysis Reported net income · Q3 2025
$859M
EX-99 · Oct 30, 2025
Reported net income · Q3 2025
$2.22
-100.0% vs prior quarter computed from stated figures
EX-99 · Oct 30, 2025
Adjusted net income · Q3 2025
$1.2B
+35.7% vs prior quarter computed from stated figures
EX-99 · Oct 30, 2025
Net income · Q3 2025
$ 33
-100.0% vs prior quarter computed from stated figures
EX-99 · Oct 30, 2025

Headline figures

MetricQ3 2025Prior qtrYear ago
Earnings Analysis Reported net income$859 million$884 million—
Reported net income$2.22$884 million—
Operating income63.6%63.8%—
Adjusted operating income25.6%25.7%—
Adjusted net income$1.2 billion$884 million—
Net EPS3.2 %6.9 %—
Net income$ 33$884 million—

EX-99 · Oct 30, 2025

Guidance · company-stated

Direction: Raised

Revenue

“2025 Outlook Based on our sales momentum, sustained demand for our products and commitment to margin expansion, we are raising our full year 2025 guidance and now expect organic net sales growth (2) of 9.8% to 10.2% and adjusted net earnings per diluted share (2) to be in the range of $13.50 to $13.60.”

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

STRYKER REPORTS THIRD QUARTER 2025 OPERATING RESULTS

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “2025 Outlook Based on our sales momentum, sustained demand for our products and commitment to margin expansion, we are raising our full year 2025 guidance and now expect organic net sales growth (2) of 9.8% to 10.2% and adjusted net earnings per diluted share (2) to be in the range of $13.50 to $13.60.”

Revenue — Raised (“raising”)
“2025 Outlook Based on our sales momentum, sustained demand for our products and commitment to margin expansion, we are raising our full year 2025 guidance and now expect organic net sales growth (2) of 9.8% to 10.2% and adjusted net earnings per diluted share (2) to be in the range of $13.50 to $13.60.”

Classified from the release's primary full-year outlook statement.

Strategy & priorities

2025 Outlook Based on our sales momentum, sustained demand for our products and commitment to margin expansion, we are raising our full year 2025 guidance and now expect organic net sales growth (2) of 9.8% to 10.2% and adjusted net earnings per diluted share (2) to be in the range of $13.50 to $13.60.

SEC original ↗Stryker Corporation — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Risks & headwinds

Caution Concerning Forward-Looking Statements This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements.

SEC original ↗Stryker Corporation — Earnings release (8-K exhibit)EX-99Oct 30, 2025

What changed vs prior quarter

Guidance direction — prior quarter: Raised; this quarter: Raised

SEC original ↗Stryker Corporation — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Earnings Analysis Reported net income — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Stryker Corporation — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Reported net income — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Stryker Corporation — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Documents

Earnings deck slides

1 deck with slide view

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

65 documents

Earnings releases

25 documents

Presentations

1 document

Transcripts

0 documents

No transcripts for Stryker Corporation are held in this edition of the library.

Mentioned by

4 companies

Other tracked companies whose held documents mention Stryker Corporation by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.